It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
The intervention showed no clear difference in adverse events (low certainty).
It is very uncertain whether other prokinetics changes adverse events compared with domperidone 10mg three times a day (very low certainty).
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).